United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $452.07, for a total value of $10,171,575.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $429.25, for a total transaction of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.50, for a total transaction of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $427.41, for a total transaction of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $440.35, for a total transaction of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $450.24, for a total transaction of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $421.80, for a total transaction of $9,490,500.00.
• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $416.35, for a total value of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total value of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The stock was sold at an average price of $392.21, for a total value of $1,961,050.00.
• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The stock was sold at an average price of $397.41, for a total value of $4,520,538.75.

United Therapeutics Stock Performance

United Therapeutics stock opened at $461.54 on Thursday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $479.50. The firm has a market capitalization of $19.87 billion, a price-to-earnings ratio of 17.49, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. The stock’s fifty day moving average is $429.43 and its two-hundred day moving average is $347.36.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.39 EPS. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Clearstead Advisors LLC raised its holdings in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 23 shares during the last quarter. Bessemer Group Inc. grew its position in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 28 shares during the period. Archer Investment Corp grew its position in shares of United Therapeutics by 9.5% in the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 31 shares during the period. F m Investments LLC increased its stake in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after purchasing an additional 33 shares during the last quarter. Finally, HB Wealth Management LLC lifted its position in United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after buying an additional 35 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings raised shares of United Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, November 7th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research report on Wednesday, October 29th. Wells Fargo & Company upped their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Oppenheimer raised their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, HC Wainwright boosted their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $503.90.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.